This represents an important step in advancing the “FFAI + AIXC” dual-flywheel, dual-bridge, and dual-listed company framework and supports the ongoing development of EAI + Crypto initiatives aimed at bridging Web2 and Web3.FFAI will continue advancing its EAI ecosystem while progressing toward key product milestones, including the first FX Super One pre-production vehicle coming off the U.S. line by year-end and the first delivery in the UAE on November 27.AIxC could benefit FFAI across five key areas: fin ...

Core Insights - BioSyent Inc. reported strong financial results for Q3 and YTD 2025, with total company sales increasing by 28% in Q3 and 27% year-to-date, driven by growth in both Canadian and international pharmaceutical sales [1][2] Financial Performance - Canadian Pharma Sales reached CAD 9,864,254 in Q3 2025, a 19% increase compared to Q3 2024, and CAD 28,351,130 year-to-date, up 16% [1] - International Pharma Sales surged to CAD 1,153,742 in Q3 2025, a remarkable 94% increase year-over-year, and CAD 3,134,572 year-to-date, reflecting a 316% growth [1] - Legacy Business Sales also saw significant growth, with Q3 2025 sales of CAD 1,203,808, an 83% increase, and year-to-date sales of CAD 1,894,358, up 73% [1] - Total Company Sales for Q3 2025 were CAD 12,221,804, a 28% increase, and CAD 33,380,060 year-to-date, a 27% increase [1][7] - EBITDA for Q3 2025 was CAD 3,632,399, a 27% increase, with a consistent EBITDA margin of 30% [1][7] - Net Income After Taxes (NIAT) for Q3 2025 was CAD 2,682,340, a 16% increase, and CAD 7,020,444 year-to-date, up 24% [1][7] Business Highlights - The company’s products, FeraMAX® and Tibella® / Tibelia®, continue to show profitable sales growth both domestically and internationally [2] - The acquisition of worldwide rights to Tibella® / Tibelia® in September 2024 has met initial expectations for sales and profit growth [2] Shareholder Information - BioSyent has declared a quarterly cash dividend of CAD 0.05 per common share, with the next payment scheduled for December 15, 2025 [5] - The company repurchased 19,500 common shares under a Normal Course Issuer Bid (NCIB) during YTD 2025 [5] - As of September 30, 2025, the company had 11,262,282 common shares outstanding [6] Balance Sheet Overview - Total assets as of September 30, 2025, were CAD 47,785,381, a 16% increase from CAD 41,359,450 at the end of 2024 [9] - Current assets increased by 47% to CAD 35,969,294, driven by a significant rise in trade and other receivables [9] - Total equity rose by 14% to CAD 39,902,869, reflecting the company's strong financial position [9]

Core Points - Namib Minerals will host a webcast and conference call for a business update on November 24, 2025, at 8:00 AM ET [1] - The company operates in the African gold mining sector, with a focus on Zimbabwe and the Democratic Republic of Congo [4] Company Information - Namib Minerals is a gold producer, developer, and explorer, significantly contributing to Africa's mining industry [4] - The company currently operates the How Mine, an underground gold mine in Zimbabwe, and plans to restart two additional assets in Zimbabwe [4] - Namib Minerals also has exploration assets in the Democratic Republic of Congo [4] Investor Engagement - Interested parties can access the live conference call via the company's Investor Relations website, and an archived replay will be available after the event [2] - Shareholders can submit questions for the management during the webcast by emailing the investor relations team [3]

Core Points - BioSyent Inc. has declared a quarterly dividend of $0.05 per common share, payable on December 15, 2025, to shareholders of record on November 28, 2025 [1] - The dividend for the fourth quarter of 2025 is consistent with the third quarter of 2025, indicating stable dividend policy [1] - The dividend qualifies as an 'eligible dividend' for Canadian income tax purposes [1] Company Overview - BioSyent Inc. is a profitable growth-oriented specialty pharmaceutical company listed on the TSX Venture Exchange under the symbol "RX" [2] - The company focuses on in-licensing or acquiring innovative pharmaceutical and healthcare products that are safe, effective, and have a proven track record [2] - BioSyent markets its products through community, specialty, and international business units to support healthcare professionals [2] Share Information - As of the date of the press release, BioSyent has 11,262,282 common shares outstanding [3]

Core Insights - Domo has partnered with Formula 1 driver Alex Albon to demonstrate the impact of data on performance in racing and business [2][4][6] - The collaboration will run through the 2026 season and includes various initiatives aimed at enhancing fan engagement and showcasing data-driven decision-making [2][4][5] Company Overview - Domo is an AI and Data Products platform that enables businesses to leverage data and AI for value creation [7] - The platform supports users in preparing, visualizing, automating, and distributing data products, enhancing the overall data journey [7] Partnership Details - The partnership will feature exclusive content, interactive experiences, and VIP hospitality opportunities at select Formula 1 races [5][6] - Domo and Albon aim to highlight the intersection of human instinct and data-driven intelligence in achieving measurable results [3][4] Industry Context - The collaboration emphasizes the importance of data in modern racing, where every decision is informed by billions of data points, paralleling the best practices in business [4][6] - The initiative aims to redefine fan engagement in Formula 1 by turning insights into impactful experiences [7]

SCOTTSDALE, Ariz., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Meritage Homes Corporation (NYSE: MTH, “Meritage” or the “Company”), the fifth-largest homebuilder in the U.S., today announced that its Board of Directors has declared a quarterly dividend of $0.43 per share. This dividend is payable on December 31, 2025 to shareholders of record as of the close of trading on December 17, 2025. As of November 20, 2025, Meritage has repurchased $128 million of shares in the fourth quarter and $273 million of shares on a y ...

Los Angeles, CA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- OFA Group (NASDAQ: OFAL) announced today that development of its real-world-asset (RWA) platform, Hearth, created by its wholly owned subsidiary Hearth Labs, Inc., remains on schedule for a full release by late 2025 or early Q1 2026. Hearth is designed as a unified, blockchain-native infrastructure system that allows qualified real estate and other income-producing assets to be validated, structured, tokenized, and managed on-chain. The platform integrates ...

ATLANTA, GA, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company”, “Regional”, “we”, “us” or “our”) (OTCQB: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB) (OTCQB:RHEPZ), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, today announced its financial results for the third quarter ended September 30, 2025. THIRD QUARTER 2025 FINANCIAL RESULTS Reported revenue of $15.1 millionGenerated GAAP net income ...

Now Standard in Siemans’ Flotherm™ Comparison Between EROM Model and Average of Measured Values ROHM's EROM models achieve high accuracy with a measurement deviation within ±5% for both surface temperature (ΔT) and thermal resistance. Santa Clara, CA and Kyoto, Japan, Nov. 20, 2025 (GLOBE NEWSWIRE) -- ROHM Semiconductor today announced its expanded lineup of EROM (Embeddable BCI-ROM) models for shunt resistors now available on ROHM’s website. In addition, these models are now standard in Siemens’ electro ...

Vancouver, BC, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour”, “SYH” or the “Company”) is pleased to announce that it has engaged Emerging Markets Consulting, LLC (“EMC”), for a 12-month marketing and investor awareness campaign, commencing on November 20th, 2025, for a upfront, non-refundable fee of USD $200,000. Pursuant to an agreement dated November 20th, 2025, EMC will assist the Company with the design, development, and dissemina ...